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Abstract: Blepharitis is a common inflammatory disease of the eyelid. Posterior blepharitis 
affects the posterior lamella of the eyelid and involves inflammation of the meibomian glands, 
whereas anterior blepharitis affects the anterior lamella of the eyelid and the eyelashes; either 
version can be inflammatory or infectious in nature. Each of these conditions can incite or 
propagate the other; anterior blepharitis, if not treated, can lead to meibomian gland disease, 
and  vice  versa.  Blepharitis  is  typically  chronic,  and  can  be  associated  with  a  variety  of 
systemic diseases such as dermatitis, as well as ocular diseases such as dry eye, conjunctivitis, 
or keratitis. The standard treatment regimen historically consists of lid hygiene with warm 
compresses and eyelid scrubs, although these treatment modalities may have limited efficacy 
for many patients, especially those with more severe disease. Adjunctive treatment includes 
systemic and topical antibiotics, topical corticosteroids, and tear replacement therapy. Topical 
antibiotics are recommended to decrease the bacterial load, and topical corticosteroids may 
help in cases of severe inflammation. Azithromycin ophthalmic solution 1% in DuraSite® 
(AzaSite®; Inspire Pharmaceuticals, Durham, North Carolina, USA) has been proposed as a 
novel treatment for posterior blepharitis, based on its well-known anti-infective profile, its anti-
inflammatory properties, its excellent tissue penetration, and its regulatory approval for the 
treatment of bacterial conjunctivitis. This review focuses on an off-label indication for topical 
azithromycin 1% in DuraSite for the treatment of blepharitis.
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Introduction
Blepharitis is one of the most common ocular surface disorders encountered by eye care 
professionals. However, the condition is frequently overlooked due to its   multifactorial 
etiology and the variability of the presenting signs and symptoms. It often presents in 
combination with other ocular surface diseases, while it may also present as a standalone 
condition, further contributing to its underdiagnosis in clinical settings.1   Classically, 
several forms of the disease have been described,2,3 most of which are chronic in 
nature.1,4 The disease can be broadly categorized into anterior and posterior, with the 
former involving an infectious and inflammatory condition of the external lamella of 
the eyelids and lashes, and the latter involving inflammation of the inner lamella of the 
eyelids and the meibomian glands, associated with an altered composition of meibomian 
gland secretions. Posterior blepharitis is also referred to as meibomian gland disease 
(MGD). Compared with patients with anterior blepharitis, those with posterior blepharitis 
(MGD) tend to be older and may present with a longer history of symptoms. Although 
the disease typically first manifests in middle age, it can also present in childhood.5Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Clinical symptoms are usually chronic and include 
  burning, grittiness, dryness or a foreign body sensation, 
redness, crusty eyelids, heavy eyelids, or fluctuating vision. 
Clinical signs include lid margin hyperemia, crusting of the 
lashes, plugging or inspissation of the meibomian gland 
orifices, abnormal, thickened meibomian gland secretions, 
foamy tears, and tear film debris or an unstable tear film.
Interestingly, there is a paucity of information on 
the   epidemiology and prevalence rates of blepharitis.5 A 
recent survey indicated that blepharitis may be present in 
37%–47% of all patients seen by ophthalmologists and 
optometrists.6 The same survey found that age is a factor in 
the   presentation – men older than 65 years and women aged 
between 46 and 65 years were most often predisposed to pos-
terior blepharitis.6 Overall published prevalence rates range 
from 12% to 47%,6–9 yet some of these studies have inherent 
limitations, including a relatively small sample size8,9 or an 
inherent bias in survey responses due to the known study 
sponsorship.7 Prevalence rates may be further confounded by 
the diagnostic confusion resulting from the overlap of clinical 
signs and symptoms of blepharitis with those of other ocular 
surface diseases such as dry eye. A study by Macsai et al10 
reported a significant overlap in symptoms between patients 
with dry eye disease and blepharitis; 68% of patients older 
than 60 years presented with signs and symptoms of both 
diseases. Such results may be due to the prevalence of dry 
eye disease presenting as a coexisting condition along with 
blepharitis in this population or the presence of a secondary 
keratoconjunctivitis sicca due to evaporative tear loss that 
may be evident in up to 50% of patients with blepharitis.5
Most cases of chronic blepharitis, whether anterior or 
posterior, are associated with a bacterial component, usually 
consisting of gram-positive organisms such as staphylococcal 
species.5 However, due to the variety of associated bacteria, 
the wide range of clinical signs and symptoms and the 
incidence of additional comorbid ocular diseases, the current 
therapeutic goals are aimed at chronic disease management 
rather than a cure of the condition.
At present, there is no US Food and Drug Administration 
(FDA)-approved definitive therapy for either anterior or 
  posterior blepharitis in the United States.1 Because both 
acute and chronic forms of the disease involve the presence 
of inflammation and bacteria, a comprehensive therapy 
that offers both antibiotic and anti-inflammatory   properties 
  coupled with good penetration into the lid tissue and 
  convenient dosing may prove beneficial for this condition.
Azithromycin ophthalmic solution 1% in DuraSite® 
(AzaSite®; Inspire Pharmaceuticals, Durham, North Carolina, 
USA) has been proposed as a novel treatment for blepharitis. 
Azithromycin, like erythromycin (another macrolide) and 
doxycycline, has been historically shown to have anti-
inflammatory properties,11,12 and to improve clinical signs 
and symptoms of blepharitis after oral administration.13 An 
effective topical delivery system for azithromycin could 
potentially deliver the same effects without the systemic side 
effects associated with oral administration. Topical delivery 
of ophthalmic preparations can be advantageous by delivering 
high drug concentrations directly to the ocular surface, yet 
challenges remain with this delivery system. Most notably, 
rapid clearance through the nasolacrimal duct, dilution through 
the production of reflex tearing, and protein binding are all 
concerns with topical ophthalmic delivery of antibiotic medica-
tions.14,15 Furthermore, the azithromycin molecule is extremely 
lipophilic, making a stable aqueous formulation of the drug 
historically difficult to manufacture. However, when coupled 
with the DuraSite drug delivery vehicle (which contains 
polycarbophil), azithromycin can form a stable aqueous for-
mulation, thus enhancing its stability and bioavailability on the 
ocular surface. When azithromycin is delivered via   DuraSite, 
it binds to the mucin-coated surfaces of the eye (including 
the palpebral conjunctiva), resulting in the formation of a 
sustained-release gel that prolongs the release and availability 
of the drug on the ocular surface and enhances the penetration 
of the drug into the eyelids, conjunctiva, and cornea,16,17 thus 
increasing its potential as a treatment for blepharitis.
This review discusses the antibiotic and anti-inflammatory 
properties of this broad-spectrum macrolide antibiotic, as 
well as off-label studies of the drug in the DuraSite delivery 
vehicle for the treatment of blepharitis.
Development of ophthalmic  
azithromycin
Broad-spectrum antibacterial coverage continues to be a 
challenge while developing new antibiotics for ophthalmic 
anti-infective therapy.18 With increasing resistance to 
fluoroquinolones,19,20 there is a need to have a wide variety 
of antibiotics of different classes and mechanisms of action 
available to treat infections.
Azithromycin is a well-known, broad-spectrum macrolide 
antibiotic that has been available in oral form in the United 
States since 1992. Prior to the introduction of AzaSite, 
the only commercially available macrolide antibiotic for 
ophthalmic use was erythromycin. Structurally, azithromycin 
contains nitrogen in its macrolide ring, whereas erythromycin 
contains a methyl group, which may explain azithromycin’s 
broader antibiotic spectrum and improved potency against Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
683
Azithromycin for blepharitis
gram-negative microorganisms.21,22 Consequently, it was 
an excellent candidate for development into an ophthalmic 
formulation. Azithromycin demonstrates potency against 
gram-positive, gram-negative, atypical bacteria, and 
  chlamydia. Azithromycin’s antibiotic properties are due to 
the inhibition of bacterial protein synthesis by its binding to 
the 50S ribosomal subunit of susceptible microorganisms. 
Furthermore, its pharmacokinetic properties lend themselves 
to once- or twice-daily dosing, which may be beneficial for 
patient compliance.18
Unlike most macrolides, azithromycin is distinguished 
by its high tissue distribution and prolonged elimination 
half-life.17 Animal studies confirmed that, when   reconstituted 
from its dry form, aqueous formulations of azithromycin had 
higher tissue concentration levels than that of   clarithromycin.23 
A single topical dose in healthy individuals found 
azithromycin to achieve significant tissue concentrations and 
maintain those levels for up to 24 hours.24
Ophthalmic uses of azithromycin
In ophthalmology, oral azithromycin has been used to treat 
trachoma and adult inclusion conjunctivitis. In 2007, the 
topical formulation of the drug was approved for ophthalmic 
use in the United States for the treatment of bacterial con-
junctivitis caused by susceptible isolates of CDC coryneform 
group G, Haemophilus influenzae, Staphylococcus aureus, 
Streptococcus mitis group, and Streptococcus pneumoniae.25 
In phase 3 studies, azithromycin in an ophthalmic formulation 
was shown to have a wide spectrum of coverage, as well as 
increased tissue penetration and persistence when compared 
with other common antibiotics18 (Table 1). When compared 
with tobramycin for the treatment of bacterial conjunctivitis, 
azithromycin was shown to have equivalent outcomes with 
fewer doses.26 Furthermore, the results of these phase 3 
trials are similar to those for other commonly used topical 
antibiotics including fluoroquinolones.19,27–29 AzaSite was 
also recommended by the Centers for Disease Control and 
Prevention as the treatment of choice for neonatal prophylaxis 
of chlamydia during the recent shortage of erythromycin 
ointment in the United States.
Anti-inflammatory properties
Through almost 2 decades of study, while azithromycin 
was available for the treatment of systemic infections, 
it was discovered that macrolide antibiotics such as 
  azithromycin exhibit anti-inflammatory properties. Studies 
have   demonstrated that they can inhibit the production of 
proinflammatory cytokines30 and the production of matrix 
metalloproteinases (MMPs).30 Although the specific anti-
inflammatory mechanism of action remains unknown, the 
suppression of the nuclear transcription factor nuclear factor 
kappa B (NF-κB) has been shown to play a role.12,30–32
Furthermore, the concentration of macrolide antibiotics 
such as azithromycin within polymophonuclear leukocytes 
(PMNs) may also modulate their role in infection-mediated 
inflammation.30 Research has shown that systemically 
administered azithromycin acts as both an   immunomodulator 
and an anti-infective in patients with chronic respiratory 
diseases.30–32
With respect to ocular inflammatory diseases, an 
in vitro study found azithromycin in DuraSite as effective 
in   suppressing MMPs in the corneal epithelium and 
endothelium as doxycycline (a tetracycline analog with 
known anti-inflammatory properties) in both human and 
bovine cells.12 However, the clinical significance of this 
effect in vivo is unknown. MMPs have been implicated 
several ocular surface diseases, including blepharitis. 
Zymosan, a fungal toll-like receptor-2 ligand that stimulates 
production of inflammatory mediators in corneal epithelial 
cells, has been shown to be inhibited by treatment with 
azithromycin, suggesting another anti-inflammatory 
mechanism of action for azithromycin in ocular tissue.33 
Macrophage and dendritic cell infiltration into the cornea 
has also been mitigated by topical azithromycin use in a 
mouse study of keratitis.34
Limitations of current therapy  
for blepharitis
Although blepharitis is a common ocular disorder, there 
is no consensus on standard management. Since anterior 
blepharitis is commonly associated with an infectious 
condition on the lid margin, typically gram positive in nature, 
treatment options usually include antibiotic ointments such 
as bacitracin and erythromycin, as well as lid hygiene with 
warm compresses and commercial lid scrubs.
Table  1  Bacterial  eradication  rates  with  azithromycin  1%  in 
DuraSite
Organism Bacterial 
eradication, %
Clinical 
resolution, %
Staphylococcus aureus 82.4 70.6
Staphylococcus epidermidis 75 100
Streptococcus mitis group 100 100
Streptococcus pneumoniae 87.3 85.5
Haemophilus influenzae 93 89.5
Note: evaluations occurred on day 6.
Adapted from Friedlander and Protzko 2007.18Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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The treatment of posterior blepharitis involves therapy to 
relieve inflammation on the lid margin, kill pathogenic bacteria, 
unclog the meibomian glands, and restore the normal character 
of the meibomian gland secretions. The classic approach 
involves (1) warm compresses and lid massage to open and 
unclog the meibomian glands, (2) antibiotic   ointments for any 
infectious component, and (3) oral   tetracyclines for their anti-
inflammatory effect on the meibomian glands, their ability to 
improve the quality of the meibomian secretions over time, 
and their antimicrobial effect.
Topical corticosteroids are often used to treat severe 
symptoms in patients with lid margin disease, whether they 
suffer from anterior or posterior disease. However, although 
topical corticosteroids may provide immediate relief, they do 
not treat the underlying pathophysiology of the condition, 
and should only be used for the short term, due to the risk 
of steroid-related complications.
Unfortunately, classical therapy described earlier often 
falls short due to the chronic nature of the disease and the 
need to maintain chronic therapy in many patients, as well 
as the side effects of the treatment regimen itself. Patients 
often report that antibiotic ointments are difficult to apply and 
blur their vision. Furthermore, oral tetracycline compounds 
are often poorly tolerated due to systemic side effects of 
gastrointestinal upset, sun sensitivity, or yeast infections 
in women and require weeks to become effective. Finally, 
only few patients are compliant with warm compresses or 
lid scrubs after a few weeks, despite the fact that chronic 
therapy with these measures is often required to maintain 
control of the condition.
Accordingly, the classical treatment measures for 
blepharitis are often inadequate, and there continues to 
be a need for better treatment modalities. Several studies 
regarding novel treatments of blepharitis and those analyzing 
the efficacy of topical azithromycin in the DuraSite drug 
delivery vehicle are under way.
Current azithromycin studies
Azithromycin 1% in DuraSite (AzaSite) is the only FDA-
approved topical formulation of azithromycin available and 
marketed in the United States. It is indicated for the treatment 
of bacterial conjunctivitis;25 the studies reviewed in this 
section discuss off-label uses of the medication.
Several animal studies that have been performed 
concluded that, after topical administration of AzaSite, high 
concentrations of azithromycin can be demonstrated in ocular 
surface tissues. In one such study in which AzaSite was 
administered according to the FDA-indicated dosing regimen 
for bacterial conjunctivitis (twice daily [BID] for 2 days 
followed by once daily [QD] for 5 days), peak concentrations 
of azithromycin more than 200 µg/g of tissue were achieved 
in human eyelid tissue as the drug accumulated over the 
7 days of therapy. Furthermore, 5 days after discontinuing 
the medication, tissue concentrations of azithromycin more 
than 50 µg/g were still present in the eyelids.18 Similar 
results were found for corneal and conjunctival samples in 
this study. In contrast, other studies have demonstrated that, 
when azithromycin in aqueous solution without DuraSite was 
administered topically, the concentrations of azithromycin in 
ocular surface tissues were negligible.17 Taken together, these 
studies demonstrate that the combination of azithromycin 
and the DuraSite vehicle allows the drug to be absorbed into 
ocular surface tissues in high concentrations.
Another study was performed in humans who were 
scheduled to undergo cataract surgery and received AzaSite 
BID for 2 days then QD for an additional 5 days prior to 
surgery. Conjunctival biopsies were taken at the time of 
surgery to determine the concentration of azithromycin 
in the tissue. Similar to the animal studies, conjunctival 
concentrations of azithromycin more than 300 µg/mL were 
found after 7 days of therapy, with levels persisting above 
50 µg/g for 5 days after stopping the drug.35 These animal 
and human studies suggest that the drug penetrates into 
ocular surface tissues in high concentrations and persists in 
therapeutic concentrations for several days after therapy is 
discontinued.17,33
The high levels of azithromycin, which can be achieved 
in ocular surface tissues, particularly eyelids, after topical 
administration when combined with the DuraSite delivery 
vehicle, and the degree to which these levels persist after 
discontinuing the drug, distinguish azithromycin in DuraSite 
from other commonly used topical antibiotics such as 
fluoroquinolones. For example, another postmarketing 
study compared AzaSite 1% and moxifloxacin 0.5% (an 
ocular antibiotic commonly prescribed for the treatment of 
bacterial conjunctivitis) to determine the pharmacokinetic 
parameters of the drops after a single instillation into healthy 
human conjunctiva (N = 48).24 Azithromycin tissue con-
centrations peaked at 30 minutes after administration and 
remained high at therapeutic concentrations at 24 hours, 
whereas moxifloxacin concentrations peaked at 2 hours after 
administration and were undetectable at 24 hours, illustrating 
the differences in tissue absorption and clearance between 
topical azithromycin and fluoroquinolones.24 Conversely, 
other studies have demonstrated that concentrations of 
moxifloxacin in the aqueous humor are significantly higher Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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than those of azithromycin after topical administration.33 
These results suggest that azithromycin tends to partition 
primarily within tissue, rather than in aqueous solution, 
whereas fluoroquinolones such as moxifloxacin partition 
readily in aqueous solution.35
Since azithromycin has both antibacterial and anti-
inflammatory properties that may make it a viable treatment 
option for chronic MGD, the author recently performed a 
2-week study comparing the efficacy of topical azithromycin 
1% in the DuraSite drug delivery vehicle (AzaSite) combined 
with warm compresses to warm compresses alone for the 
treatment of posterior blepharitis.36 In this study (N = 21), 
10 patients were randomized to the study drug and warm 
compresses; 11 received warm compresses alone. Patients 
in the azithromycin group showed a statistically significant 
improvement over baseline in the extent of lid margin 
redness (P , 0.001, Figure 1), meibomian gland plugging 
(P , 0.001, Figure 2), and quality of meibomian gland 
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Figure 1 effects of topical azithromycin in combination with warm compresses, compared with warm compress-only group on lid redness.
Note: The clinical signs were rated by the investigator as 0 = normal, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe.
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Figure 2 effects of topical azithromycin in combination with warm compresses, compared with warm compress-only group on meibomian gland plugging.
Note: The clinical signs were rated by the investigator as 0 = normal, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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secretions (P , 0.001, Figure 3); patients in the warm 
compress-only group did not show a statistically significant 
improvement in any of these parameters. Of interest, 44% 
of the patients in the azithromycin group showed complete 
resolution of their plugging in at least 1 eye compared to 
none in the compress-only group; almost a quarter of those 
in the azithromycin group also showed a normalization of the 
meibomian gland secretions after 2 weeks of therapy (none 
in the compress-only group had normalization). Further, 
there were only minor adverse events (vision blur and eye 
irritation) in the azithromycin group.
A second multicenter pilot study37 enrolled 76 patients 
with moderate to severe blepharitis, randomized to warm 
compresses alone or warm compresses and topical 1% 
azithromycin, for a 4-week treatment period. At week 1, 
investigators rated the efficacy of azithromycin as excellent 
or good in 44% of patients in the azithromycin group, 
compared with only 15% in the compress-only group. This 
improved to 70% in the azithromycin group after 4 weeks 
of therapy, compared to 48% in the compress-only group. 
More importantly, the positive improvements achieved in 
the azithromycin group persisted as long as 2 weeks after 
therapy had concluded. Although the data did not reach 
statistical significance between the 2 groups, there was a 
trend toward improvement in the azithromycin group for 
eyelid swelling, quality of the meibomian gland secretions, 
and ocular pain or burning.
Another open-label study38,39 of 26 patients with   moderate 
to severe blepharitis evaluated changes in the signs and 
symptoms of anterior and posterior blepharitis after a 
4-week course of treatment with topical azithromycin 1% 
in DuraSite (AzaSite). Patients were prohibited from using 
warm compresses in this study. Patient-rated symptom 
scores for itching, foreign body sensation, ocular dryness, 
ocular burning, and swollen eyelids were all statistically 
significantly improved from baseline levels after 4 weeks of 
therapy (P , 0.001 for each symptom), and the improvement 
persisted for 4 weeks after stopping therapy. This supported 
the investigator-rated assessment of the clinical signs of 
blepharitis, which demonstrated statistically significant 
improvements in lid margin and conjunctival hyperemia, 
meibomian gland plugging, and ocular discharge after 
4 weeks of therapy, which also persisted for 4 weeks after 
stopping therapy (last visit on day 57).
These studies suggest that topical azithromycin 1% in 
the DuraSite drug delivery vehicle may be effective as a 
standalone treatment for blepharitis as well as an adjunctive 
therapy with warm compresses; the studies demonstrate that 
topical azithromycin is more successful in treating the signs 
and symptoms of blepharitis than just mechanical therapy 
(warm compresses) alone. However, these studies are limited 
by their small size, open-label design, lack of a control arm, 
and potential bias due to the relationships of some of the 
investigators with the study sponsor.
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Figure 3 effects of topical azithromycin in combination with warm compresses, compared with warm compress-only group on quality of meibomian gland secretion.
Note: The clinical signs were rated by the investigator as 0 = normal, 1 = mild, 2 = moderate, 3 = severe, and 4 = obstructed.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Another study by Foulks et al40 evaluated the physical 
properties of the meibomian secretions in patients with 
MGD. This study demonstrated that the phase transition 
temperature and lipid ordering of the meibomian secretions 
trended toward normal after once-daily dosing of topical 
azithromycin 1% in DuraSite for 4 weeks. These results 
correlate with the time course of the clinical improvements 
in the quality of the meibomian secretions noted in the afore-
mentioned study and suggest that azithromycin may have a 
direct effect on the meibomian glands or their secretions. 
Further study is warranted in this area.
These pilot studies have led to the initiation of larger, 
  prospective, multicenter studies of the effect of topical 
azithromycin 1% in the DuraSite drug delivery vehicle 
on blepharitis (clinicaltrials.gov NCT00894530 and 
NCT00892970). The 2 phase 2, randomized, double-masked, 
placebo-controlled studies of different lengths (2 and 
4 weeks, respectively) have recently been completed and will 
evaluate both primary and secondary outcome measures in 
patients with blepharitis. In these studies, primary outcome 
measure is eyelid margin erythema and secondary outcomes 
include additional clinical signs and clinical symptoms of 
blepharitis.
Another study (clinicaltrials.gov NCT00803452) 
  evaluates the effects of oral doxycycline, oral essential 
fatty acids, or topical azithromycin 1% in the DuraSite drug 
delivery vehicle in expressing meibomian gland secretions 
before and after treatment in subjects with MGD and/or dry 
eye disease. In this prospective study, doxycycline is dosed 
at 100 µg BID for 2 months, essential fatty acids are dosed 
at 1,000 µg/day for 2 months, and topical azithromycin 1% 
in the DuraSite drug delivery vehicle is dosed once daily 
for 1 month.
Conclusions
The known antibacterial and anti-inflammatory aspects of 
topical azithromycin 1% in DuraSite and the promising 
results from early studies in subjects with chronic blepharitis 
(both anterior and posterior) are encouraging, although 
the results are limited by the study designs; further studies 
are warranted, and a randomized, prospective, placebo-
controlled trial has recently been completed. In a chronic 
and common disease such as blepharitis that currently has no 
single approved treatment, is complicated in its management, 
and has wide-ranging signs and symptoms, treatments that 
rapidly improve both clinical and self-reported signs and 
symptoms are welcome.
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